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Hypomethylation of CYP2E1 and DUSP22 Promoters
Associated With Disease Activity and Erosive Disease
Among Rheumatoid Arthritis Patients
Amanda Mok ,1 Brooke Rhead,1 Calliope Holingue,1 Xiaorong Shao,1 Hong L. Quach,1
Diana Quach,1 Elizabeth Sinclair,2 Jonathan Graf,2 John Imboden,2 Thomas Link,2
Ruby Harrison,2 Vladimir Chernitskiy,2 Lisa F. Barcellos,1 and Lindsey A. Criswell2
Objective. Epigenetic modifications have previously
been associated with rheumatoid arthritis (RA). In this
study, we aimed to determine whether differential DNA
methylation in peripheral blood cell subpopulations is asso-
ciated with any of 4 clinical outcomes among RA patients.
Methods. Peripheral blood samples were obtained
from 63 patients in the University of California, San
Francisco RA cohort (all satisfied the American College
of Rheumatology classification criteria; 57 were seroposi-
tive for rheumatoid factor and/or anti–cyclic citrullinated
protein). Fluorescence-activated cell sorting was used to
separate the cells into 4 immune cell subpopulations
(CD14+ monocytes, CD19+ B cells, CD4+ naive T cells,
and CD4+ memory T cells) per individual, and 229 epi-
genome-wide DNA methylation profiles were generated
using Illumina HumanMethylation450 BeadChips. Dif-
ferentially methylated positions and regions associated
with the Clinical Disease Activity Index score, erosive dis-
ease, RA Articular Damage score, Sharp score, medica-
tion at time of blood draw, smoking status, and disease
duration were identified using robust regression models
and empirical Bayes variance estimators.
Results. Differential methylation of CpG sites
associated with clinical outcomes was observed in all 4
cell types. Hypomethylated regions in the CYP2E1 and
DUSP22 gene promoters were associated with active and
erosive disease, respectively. Pathway analyses suggested
that the biologic mechanisms underlying each clinical
outcome are cell type–specific. Evidence of independent
effects on DNA methylation from smoking, medication
use, and disease duration were also identified.
Conclusion. Methylation signatures specific to
RA clinical outcomes may have utility as biomarkers
or predictors of exposure, disease progression, and dis-
ease severity.
Rheumatoid arthritis (RA) is the most common
systemic autoimmune disease, with a global prevalence of
~1% (1). Although the precise model of pathogenesis is
not known, it is thought to involve the activation of both
innate and adaptive immune responses as well as the
destruction of cartilage and subchondral bone by resident
synoviocytes, leading to joint damage and disability. The
cause of RA is complex, with contributions from both
genetic and nongenetic risk factors.
The strongest genetic risk factors for RA are vari-
ants of the HLA–DRB1 gene. The shared epitope (SE)
alleles encoding the QKRRA and QRRRA amino acid
sequences at positions 70–74 explain much of the genetic
predisposition to RA (2). Recently, a large study demon-
strated that the association between the major histocom-
patibility complex (MHC) and RA is best explained by 5
amino acids: 3 in HLA–DRB1 and 1 each in HLA–B and
HLA–DPB1, of which 2 are the same as those of the shared
epitope (3). Of the 16 resulting DRB1 haplotypes, valine/
lysine/alanine at positions 11/71/74 is the most strongly
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associated with RA, and it corresponds to the DRB1*04:01
allele (3), a well-documented association (3,4).
DNA methylation is an epigenetic modification
that results from the addition of a methyl group to a cyto-
sine DNA base in the context of cytosine–phosphate–gua-
nine dinucleotide (CpG), and has been shown to
modulate gene expression as well as determinants of
higher-order DNA structure (5,6). Methylation profiles
can be maintained across cell division cycles and between
generations and may contribute to the “missing heritabil-
ity” suggested by current genome-wide association study
findings (7). In addition, DNA methylation states can be
altered by a number of environmental exposures, such as
tobacco smoke, air pollutants, paternal and maternal life-
style factors, and antibiotic use (8). Thus, DNA methyla-
tion profiles may link genetic and environmental signals
and serve as the intermediate between those risk factors
and disease susceptibility.
A growing body of epidemiologic evidence sup-
ports an association between RA and DNA methylation.
Genome-wide and candidate gene studies in RA patients
and healthy controls have demonstrated disease-associated
methylation differences in peripheral blood mononuclear
cells (PBMCs), purified Tcells and B cells, and fibroblast-
like synoviocytes (9–12). Interestingly, treatment with
methotrexate is able to revert RA-associated global hypo-
methylation in T cells and monocytes and restore regula-
tory T cell function through reduction in methylation of
the FOXP3 upstream enhancer (13,14). One proof-of-
concept study of DNA methylation at first diagnosis identi-
fied 6 CpG sites associated with response to disease-
modifying antirheumatic drugs (DMARDs) in patients
with early RA (15). However, studies to date have typically
been limited to case–control comparisons and have not
identified methylation differences specific to RA case sub-
groups or clinical outcomes.
In this study, we assessed DNA methylation signals
associated with 4 RA clinical outcomes, history of smok-
ing, medication use, and disease duration. Such signatures
may be useful as biomarkers or predictors of exposure,
disease progression, or response to treatment.
PATIENTS AND METHODS
Study participants. Participants included 63 women of
European ancestry from the RA cohort at the University of Cali-
fornia, San Francisco (UCSF), all of whom met the American
College of Rheumatology (ACR) 1987 criteria for RA (Table 1)
(16). All participants provided a peripheral blood sample for
genotyping, cell sorting, and DNA methylation profiling. The
following clinical outcomes were determined for each RA
patient: the Clinical Disease Activity Index (CDAI) score, pres-
ence of erosive disease, total Rheumatoid Arthritis Articular
Damage (RAAD) score, and modified Sharp score for all joints
(17,18). The CDAI is a sum of the tender joint count, swollen
joint count, patient’s global assessment of disease activity, and
physician’s global assessment of disease activity. It was treated as
a dichotomized variable based on the presence of active disease
(CDAI score >2.8) or remission (CDAI score ≤2.8), in accor-
dance with the ACR recommendations (19). The European
League Against Rheumatism (EULAR) criteria were used to
classify erosive disease (20). According to the EULAR classifica-
tion, erosive disease is defined as cortical breaks in at least 3 sep-
arate joints of the hands and feet as observed on radiographs,
and this was treated as a binary variable (20). The modified
Sharp score is a more detailed measure of radiographic damage,
where each hand, wrist, and foot joint is scored for erosions and
for joint space narrowing (18). The RAAD score is computed by
evaluating 35 large and small joints using a goniometer and scor-
ing them on a 3-point scale, and it may therefore capture aspects
of joint failure not reflected on radiography-based scores (21).
Study approval. Written informed consent was obtained
from all participants prior to inclusion in this study. Research
was conducted in compliance with the Declaration of Helsinki.
Institutional Review Board approval was obtained at UCSF,
where the study subjects were recruited.
Genotyping and methylation assessment. Single-nucleo-
tide polymorphism (SNP) genotyping and DNA methylation pro-
filing were performed as previously described (22). Briefly, study
participants were genotyped using Illumina HumanOmniExpress,
HumanOmniExpressExome, or Human660W-Quad microarrays,
and principal components analysis was performed using
EigenStrat to characterize genetic ancestry and account for any
heterogeneity in our study population (23). PBMCs were isolated
from whole blood, and the following cell subpopulations were
identified by fluorescence-activated cell sorting: monocytes
(CD45+CD14+), B cells (CD45+CD14–CD3–CD19+), naive CD4+
T cells (CD45+CD14–CD19–CD3+CD4+CD27+CD45RA+), as
well as memory CD4+ T cells (CD45+CD14–CD19–CD3+CD4+
CD45RA–). A total of 229 epigenome-wide DNA methylation
profiles were generated using the Illumina Infinium HumanMeth-
ylation450 BeadChip, and b values (the ratio of methylated probe
intensity to total intensities) were reported per CpG site.
Extensive quality control measures were performed,
including background signal subtraction, all sample mean
Table 1. Characteristics of the study participants at the time of
blood draw*
Seropositive, no. (%)
Anti-CCP or RF 57 (90.5)
Anti-CCP 53 (89.8)
RF 46 (75.4)
Age, mean  SD 56.4  14.8
Ever smoked, no. (%) 33 (52.4)
Disease duration, mean  SD years 14.0  10.5
Active disease (CDAI >2.8), no. (%) 45 (76.2)
Erosive disease, no. (%) 39 (63.9)
RAAD score, mean  SD 10.1  13.0
Sharp score, mean  SD 47.2  74.0
Current DMARD or anti-TNF therapy, no. (%) 52 (82.5)
* Anti-CCP = anti–cyclic citrullinated peptide; RF = rheumatoid fac-
tor; CDAI = Clinical Disease Activity Index; RAAD = Rheumatoid
Arthritis Articular Damage; DMARD = disease-modifying antirheu-
matic drug; anti-TNF = anti–tumor necrosis factor.
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normalization, and beta-mixture quantile normalization (24–26).
Samples with low detection rates (P > 0.05) in more than 20% of
sites were removed from analysis. The following sites were also
removed from analysis: CpG sites with low detection rates (P >
0.05) in more than 20% of samples, non-CpG “rs” SNP probes,
cross-reactive probes, and European-specific polymorphic CpGs
(27). In total, we retained 428,232 CpG sites in 229 samples (58
CD14+ monocyte samples, 57 CD19+ B cell samples, 56 CD4+
naive Tcell samples, and 58 CD4+memory Tcell samples).
Statistical analysis. Using the Lumi R package (28,29),
methylation b values were transformed to M values in order to
better approximate the homoscedasticity assumption in most sta-
tistical analyses. For each RA clinical outcome, robust linear
regression models were fitted to each CpG site to assess for asso-
ciation with methylation, adjusting for age, history of smoking,
genetic ancestry, DMARD treatment (methotrexate, hydroxy-
chloroquine, leflunomide), anti–tumor necrosis factor treatment
(anti-TNF; adalimumab, certolizumab, or golimumab), and dis-
ease duration at the time of blood draw. Regression models were
fitted separately for each cell type. A robust empirical Bayes pro-
cedure as implemented in the Limma R package was used to
shrink CpG-wise variances by pooling the ensemble of all CpG
sites, a technique used to improve statistical power and accuracy
when the sample size is small (30). Per the regression model, P
values were adjusted using the Bonferroni correction for 428,232
tests.
Analysis of differentially methylated regions (DMRs)
was performed as implemented in the Bumphunter R package
(31). Coefficients from the above regression models were
smoothed over genomic distance, generating candidate regions of
differentially methylated CpG sites. Statistical significance was
assigned to individual regions by calculating an empirical P value
derived from 1,000 bootstrapped results. The empirical family-
wise error rate was used to control for Type I error. Genomic
annotations were obtained from the GRCh37/hg19 UCSC Gen-
ome Browser, specifically the RefSeq gene track, CpG island
track, and chromatin state segmentation by hidden Markov
model tracks for 2 blood tissues (GM12878 and K562) (32).
Pathway analysis was performed using the missMethyl R
package in order to determine whether certain biologic pathways
are associated with RA clinical outcomes (33). Enrichment for
Gene Ontology (GO) terms was performed using genes that
contained differentially methylated CpG sites as identified from
regression modeling, while taking into account the number of
probes per gene. The Benjamini-Hochberg method was used to
control the false discovery rate (FDR) (34).
Comparisons of DNA methylation profiles associated
with each RA clinical outcome were performed in 2 ways. First,
to identify cell type–specific profiles shared among RA clinical
outcomes, 16 CpG sets were defined as the differentially meth-
ylated CpG sites associated with each RA clinical outcome per
cell type, using the following significance thresholds: Bonferroni-
adjusted P < 0.05, FDR q < 0.05, FDR q < 0.10, and unadjusted
P < 0.05. Statistical significance thresholds were varied in order
to capture DNA methylation differences that were smaller in
magnitude but consistent across multiple RA clinical outcomes
or across multiple cell types. Second, to identify DNA methyla-
tion profiles shared among RA clinical outcomes regardless of
cell type, 4 CpG sets were defined as the differentially meth-
ylated CpG sites associated with each RA clinical outcome in
any cell type at the same thresholds of statistical significance.
The pairwise overlap between CpG sets was computed as a
count (total number of CpG sites shared between 2 CpG sets)
and as a shared percentage (proportion of CpG sites in one
CpG set that were also found in a second CpG set).
RESULTS
Disease activity. Genome-wide analyses comparing
cases with active disease (CDAI >2.8; categorized as low/
minimal, moderate, and high/severe disease activity) to
cases with disease in remission (CDAI ≤2.8) identified 27
CpG sites (14 hypermethylated and 13 hypomethylated)
associated with active disease (Bonferroni-adjusted P <
0.05), independently of any history of smoking, medication
use, and disease duration (Supplementary Figure 1 and
Supplementary Table 1, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40408/abstract). We identified 1 statistically signifi-
cant DMR containing 11 CpG sites on chromosome 10
(Figure 1A). This region is hypomethylated in cases with
active disease compared to those with disease in remission
in both CD14+ monocytes and naive CD4+ T cells, and it
is located in the 50 region of cytochrome P450 2E1
(CYP2E1).
Erosive disease. Genome-wide assessment of
differential methylation associated with erosive disease
identified 84 CpG sites (10 hypermethylated and 74 hypo-
methylated; Bonferroni-adjusted P < 0.05) that were inde-
pendent of any history of smoking, medication use, and
disease duration (Supplementary Figure 2 and Supple-
mentary Table 2, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40408/abstract). Most of these sites
(74%) were identified in CD19+ B cells. DMR analyses
identified a hypomethylated region on chromosome 6
containing 10 CpG sites that was associated with erosive
disease in all 4 cell types (Figure 1B). This region over-
laps with the transcription start site of dual-specificity
phosphatase 22 (DUSP22).
RAAD score.A dose-dependent association between
RAAD scores and methylation levels was identified for
89 CpG sites genome-wide (15 hypermethylated and 74
hypomethylated; Bonferroni-adjusted P < 0.05), indepen-
dently of any history of smoking, medication use, and dis-
ease duration (Supplementary Figure 3 and Supplementary
Table 3, available at http://onlinelibrary.wiley.com/doi/10.
1002/art.40408/abstract). Most of these CpG sites were dif-
ferentially methylated only in CD14+ monocytes, with 1
CpG (cg06355652) hypomethylated in both CD14+ mono-
cytes and naive CD4+ T cells. DMR analyses did not yield
significant associations with RAAD scores.
Modified Sharp score. A total of 168 CpG sites
(139 hypermethylated and 29 hypomethylated) demon-
strated a dose-dependent association with the modified
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Sharp score (Bonferroni-adjusted P < 0.05), independently
of any history of smoking, medication use, and disease
duration (Supplementary Figure 4 and Supplementary
Table 4, available at http://onlinelibrary.wiley.com/doi/
10.1002/art.40408/abstract). Six CpG sites were differen-
tially methylated in the same direction across multiple
cell types. No regions of differential methylation were
associated with the modified Sharp score after correcting
for multiple hypothesis testing.
Comparison of DNA methylation profiles among
RA clinical outcomes. In order to identify CpG sites asso-
ciated with multiple RA clinical outcomes, we performed
intersections of CpG sets identified from the previous
analyses where each RA clinical outcome was treated sep-
arately. Methylation profiles observed in the current study
were largely unique to specific RA clinical outcomes and
to individual cell types (Figure 2A). The vast majority of
CpG sites were associated with only 1 RA clinical out-
come and were differentially methylated in only 1 cell
type. Varying the statistical significance threshold did not
change our findings (Supplementary Figures 5A–C,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.
40408/abstract). Pooling CpG sites across cell types for an
RA outcome also did not reveal any sets of CpG sites that
were differentially methylated across multiple RA clinical
outcomes (Figure 2B and Supplementary Figure 6,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.
40408/abstract).
Pathway analyses for RA clinical outcomes. Path-
way analysis of differentially methylated genes associated
with disease activity identified enrichment of 32 GO terms
(FDR q < 0.05), as summarized in Supplementary Table 5
(available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40408/abstract). Only CpG sites that were differen-
tially methylated in naive CD4+ Tcells were enriched for
GO terms. The top enriched pathways suggest dysregula-
tion of the innate immune response: positive regulation of
interferon-c (IFNc) production, negative regulation of
natural killer cell–mediated cytotoxicity, and antigen pre-
sentation (Table 2).
Pathway analysis of differentially methylated
genes associated with the modified Sharp score
Figure 1. Association between hypomethylation of differentially methylated regions (DMRs) at promoter regions and rheumatoid arthritis clinical
outcomes. Methylation differences between active and inactive disease (A) or between erosive and nonerosive disease (B) are plotted over genomic
intervals, with the DMR demarcated in green. Gene positions are denoted in purple and CpG islands in black. Red/pink regions represent pro-
moter regions, orange/yellow regions represent enhancer regions, and gray regions represent polycomb-repressed chromatin in GM12878 and
K562 cell types. The DMR on chromosome 10 associated with active disease in CD14+ monocytes and CD4+ naive T cells overlaps with the
CYP2E1 promoter (A). The DMR on chromosome 6 associated with erosive disease in all 4 immune cell types overlaps with the DUSP22 pro-
moter region (B).
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identified enrichment of 9 GO terms (FDR q < 0.05),
as summarized in Supplementary Table 6 (available at
http://onlinelibrary.wiley.com/doi/10.1002/art.40408/
abstract). The results suggest that dysregulation of volt-
age-gated calcium-channel transport and preganglionic
parasympathetic fiber development in CD14+ monocytes
plays a role in the development of radiographic erosions
as measured by the modified Sharp score (Table 2).
History of smoking. Across all regression models,
a total of 154 CpG sites (44 hypermethylated and 110
hypomethylated) showed differential methylation associ-
ated with any history of smoking (Bonferroni-adjusted P <
0.05), independently of all other covariates (Figure 3).
The results are summarized in Supplementary Table 7
(available at http://onlinelibrary.wiley.com/doi/10.1002/
art.40408/abstract). The association between smoking and
Figure 2. CpG sites associated with rheumatoid arthritis (RA) clinical outcomes are specific to outcome and to cell type. The shared percentage
reflects the proportion of CpG sites identified in each row of the CpG set that were also identified in each column of the CpG set using a signifi-
cance threshold of Bonferroni-adjusted P < 0.05. The value in each cell reflects the number of CpG sites in the intersection of row and column
CpG sets. Values on the diagonal reflect the total number of differentially methylated sites for that outcome and cell type. A, Similarity of RA
clinical outcomes by CpG methylation, keeping cell types separate. B, Similarity of RA clinical outcomes by CpG methylation, pooling cell types
together at a significance threshold of Bonferroni-adjusted P < 0.05. The following outcomes were assessed: the modified Sharp score, the
Rheumatoid Arthritis Articular Damage (RAAD) score, erosive disease (erosion), and the Clinical Disease Activity Index (CDAI) score. CD4Nv =
CD4+ naive T cells; CD4Mem = CD4+ memory T cells. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.
wiley.com/doi/10.1002/art.40408/abstract.
Table 2. Top GO pathways significantly enriched for associations with rheumatoid arthritis clinical outcomes*
GO accession no. Group/term P Cell type
No. of genes
in group
Differentially methylated
genes in group
Active disease
GO:0032729 Positive regulation of IFNc production 3.55 9 10–7 CD4 naive 61 WNT5A, LTA, HLA–A
GO:0045953 Negative regulation of natural killer cell cytotoxicity 7.82 9 10–6 CD4 naive 10 HLA–A, TAP1
GO:0002484 Antigen presentation and presentation of endogenous
peptide antigen via MHC class I via ER pathway
7.08 9 10–6 CD4 naive 9 HLA–A, TAP1
Modified Sharp score
GO:0034762 Regulation of transmembrane transport 1.81 9 10–5 CD14 424 CACNB2, KCNJ6, ANO1,
CACNA1H, CACNA1G,
CTTNBP2NL
GO:0021783 Preganglionic parasympathetic fiber development 1.18 9 10–5 CD14 16 NAV2, PLXNA4, NRP1
* GO = Gene Ontology; IFNc = interferon-c; MHC = major histocompatibility complex; ER = endoplasmic reticulum.
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DNA methylation was observed for all cell types and for
all RA clinical outcomes; ~50% of associated CpG sites
were present in naive CD4+ T cells. No regions of differ-
ential methylation or enrichment for GO terms were sig-
nificantly associated with smoking.
DMARD treatment. Results from regression mod-
eling demonstrated evidence of association between
DMARD treatment and DNA methylation for 285 CpG
sites (250 hypermethylated and 35 hypomethylated;
Bonferroni-adjusted P < 0.05), independently of all other
covariates (Figure 3). The results are summarized in Sup-
plementary Table 8 (available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40408/abstract). The majority of CpG
sites (71%) were identified in the CD14+ monocyte popu-
lation. Results from regression models for the modified
Sharp score had the highest proportion of CpG sites asso-
ciated with DMARD treatment (38%). No regions of dif-
ferential methylation or enrichment for GO terms were
associated with DMARD treatment.
Anti-TNF treatment. A total of 451 CpG sites (407
hypermethylated and 44 hypomethylated) had methylation
differences associated with anti-TNF treatment (Bonferroni-
adjusted P < 0.05), independently of all other covariates
(Figure 3). The results are summarized in Supplementary
Table 9 (available at http://onlinelibrary.wiley.com/doi/
10.1002/art.40408/abstract). A majority of this signal was
identified in naive CD4+ Tcells (77%) and was enriched
for “homophilic cell adhesion via plasma membrane
adhesion molecules” (GO term 0007156; P = 2.809 10–8).
Disease duration. Associations between disease
duration and DNA methylation were observed for 718
CpG sites (188 hypermethylated and 530 hypomethylated;
Bonferroni-adjusted P < 0.05), which was independent of
all other covariates (Figure 3). The results are summa-
rized in Supplementary Table 10 (available at http://online
library.wiley.com/doi/10.1002/art.40408/abstract). DNA
methylation levels were the most affected in memory
CD4+ T cells (74%), which also showed enrichment for
“homophilic cell adhesion via plasma membrane adhesion
molecules” (GO term 0007156; P = 1.53 9 10–8).
DISCUSSION
In this study of DNA methylation in sorted
immune cell types, we identified methylation profiles asso-
ciated with clinical outcomes of RA. Our findings indicate
that the profiles were highly specific for each clinical out-
come and for individual cell types. We also found that
medication use and disease duration at the time of blood
draw were significantly associated with DNA methylation
in specific cell types.
We identified a region of 11 hypomethylated CpG
sites near the transcription start site of CYP2E1 associated
with active disease, as indicated by the CDAI score. A
multivariate hidden Markov model trained on histone
modifications observed in chromatin immunoprecipita-
tion sequencing experiments performed on 2 blood sam-
ples predicts this region to be a promoter, suggesting that
CYP2E1 expression is elevated in the monocytes and
naive T cells of patients with active disease (35,36).
CYP2E1 is a member of the cytochrome P450 enzyme
family and is responsible for the metabolism of exogenous
substrates such as nicotine, ethanol, acetaminophen, and
aspartame (37). Expression of CYP2E1 is induced by
lipopolysaccharide and interleukin-4 (IL-4) in human
astrocytes and hepatocytes and is regulated by the oxida-
tive stress pathway in monocytes, implying some immune
function (38,39). Interestingly, alcohol consumption has
been linked to impaired priming of CD4+ T cells by den-
dritic cells and to the production of autoantibodies against
CYP2E1 (40,41). While the identified DMR reflects the
independent association between active disease and DNA
methylation after accounting for any history of smoking
and current medication use, we were unable to investigate
other environmental or dietary exposures, such as alcohol
consumption, that might contribute to the methylation of
the CYP2E1 promoter.
Figure 3. Summary of covariate analyses. Values represent the num-
ber of CpG sites whose methylation is associated with that covariate
(columns) in that cell type (rows). CpG sites were included if they
were significantly differentially methylated in any regression model.
Effects of medication and disease duration are cell type–specific.
Covariates were any history of smoking, treatment with a disease-
modifying antirheumatic drug (DMARD), treatment with an anti–
tumor necrosis factor (anti-TNF) agent, and duration of disease.
CD4Mem = CD4+ memory T cells; CD4Nv = CD4+ naive T cells.
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We also identified a region of 10 hypomethylated
CpGs near the transcription start site of DUSP22 that was
associated with erosive disease. This region overlaps with
an active promoter chromatin state in blood tissues and
was differentially methylated in all 4 cell types we exam-
ined (36). DUSP22 is a protein phosphatase involved in
MAPK signaling, and it appears to lie at the intersection
of several immune signaling pathways, including those
mediated through the T cell antigen receptor, IL-6
leukemia-inhibiting factor, and the estrogen receptor
(42,43). A study of the DUSP22-knockout mouse showed
autoimmune tendencies: splenic T cells had stronger
responses to anti-CD3 stimulation, serum levels of
proinflammatory cytokines and autoantibodies were
higher, and symptoms in an experimental autoimmune
encephalomyelitis mouse model developed faster and
were more severe (44). Hypomethylation observed among
RA cases with erosive disease in the current study should
lead to increased messenger RNA (mRNA) expression of
DUSP22. Further studies are needed to confirm the rela-
tionship between methylation and expression and to
understand the dynamics between mRNA expression and
protein levels in order to understand how DUSP22 might
contribute to erosive disease.
Examination of the differentially methylated CpG
sites using Gene Ontology identified cellular processes
underlying disease activity and severity. Disease activity was
related to differential methylation of CpG sites in genes
involved in the IFNc signaling and antigen-presentation
pathways; the finding that these effects were observed only
in naive CD4+ Tcells suggests that this population is biased
toward Th1 differentiation. In addition, pathway analysis of
the CpG sites associated with the modified Sharp score
showed dysregulation of transmembrane transport and pre-
ganglionic parasympathetic fiber development in CD14+
monocytes. Previous studies of cardiovascular autonomic
nervous system function in RA patients led to the hypothe-
sis that the equilibrium between the opposing effects of the
sympathetic and parasympathetic nervous systems has been
disrupted (45). Our results support this theory and further
highlight the role played by the autonomic nervous system
as a modulator of immune function and a possible target
for future RA therapies.
Much of the differential methylation observed for
RA clinical outcomes was present in CD14+ monocytes
and naive CD4+ T cells, which further highlights the role
of these immune subpopulations in RA pathogenesis and
disease progression. Treatment of normal synovial fibro-
blasts with an inhibitor of DNA methylation was able to
reproduce the hypomethylation and activated phenotype
observed in RA synovial fibroblasts (46). A previous
study of RA patients reported higher frequencies of
CD14+CD16+ circulating monocytes in patients with
active disease, and response to drug therapy was corre-
lated with changes in these frequencies (47,48). These cir-
culating monocytes can migrate into the synovial joint,
where they can recruit lymphocytes to the inflamed joint
and drive the polarization of CD4+ helper T cells (49).
Furthermore, activated T cells from the peripheral
immune system are able to stimulate the differentiation
of monocytes into osteoclasts, thereby contributing to
bone damage and production of radiographic lesions (50).
Thus, the interactions between monocytes and T cells in
both peripheral blood and synovial joints may prove inter-
esting for therapeutics that target disease activity and pro-
gression.
RA is a heterogeneous disease with symptom pre-
sentations and prognoses that differ between patients.
Therefore, it may be important to consider various mea-
sures of disease activity and severity in order to identify
the different biologic mechanisms that underlie disease
heterogeneity. We analyzed 4 RA clinical outcome mea-
sures: disease activity as measured by the CDAI score,
erosive disease, the RAAD score, and the modified Sharp
score. Each of these 4 measures captures different aspects
of RA disease progression and is associated with different
risk factors and prognoses. By analyzing each measure
separately, we were able to investigate the association
between RA disease heterogeneity and DNA methylation
and to identify profiles specific to each clinical outcome.
We found that DNA methylation profiles were highly
specific to each clinical outcome measure, suggesting that
different biologic processes drive different measures of
disease activity and severity. These results can help in the
development of new therapies targeted toward specific
manifestations and thus aid in the generation of patient-
specific treatment plans.
Our previous analysis in the same RA patient pop-
ulation identified predominantly hypomethylated candi-
date CpG sites in naive and memory CD4+ T cells from
the patients as compared to healthy controls (22). Com-
parison of the results from the current study of clinical
phenotypes with the previous RA case–control study did
not reveal significant overlap of differential methylation.
These findings suggest that DNA methylation changes rel-
evant to disease susceptibility in RA are largely distinct
from those that contribute to disease severity and pheno-
typic expression.
The strengths of our study include the large sam-
ple size and selection of female RA cases to minimize
confounding by sex. By sorting PBMCs before performing
DNA methylation profiling, we were able to avoid major
confounding by cell-type heterogeneity and to analyze
cell-specific effects for each RA clinical outcome. Using
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genome-wide SNP data, we were also able to compute
principal components reflecting genetic ancestry, further
avoiding potential confounding by population stratifica-
tion. Our analyses were also able to demonstrate associa-
tions between DNA methylation and any history of
smoking, medication use, and disease duration at the time
of blood draw.
Limitations of our study include its cross-sectional
nature, which limited our ability to determine causality or
temporality of these DNA methylation differences relative
to disease progression. Our RA patient sample consisted
only of women of European ancestry, thus restricting the
ability to extrapolate our results beyond this population.
DNA methylation profiling was performed on microarray
chips, and imputation or pyrosequencing must be per-
formed to assess methylation at CpG sites not assayed on
the chip. Last, we examined DNA from peripheral blood
cells and not from cells in the synovial joint. While circu-
lating immune cells can be recruited into the joint com-
partment from the periphery, we may not be capturing
local biologic processes that drive joint damage.
In summary, we have shown that different mea-
sures of RA disease activity and severity are associated
with specific DNA methylation profiles and that these
methylation differences are also highly cell type–specific.
Our results further support the premise that genetic, as
well as epigenetic, variations may drive clinical hetero-
geneity in RA.
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